Fig. 4: Anti-CD20 reduces the number of TIM1+ Bregs and enhances the expression of inflammatory factors after co-treatment with RMT1-10 in myocardial IRI.
From: The effect of TIM1+ Breg cells in myocardial ischemia-reperfusion injury
A The changes in the number TIM1+ Bregs (TIM1+ CD19+) in the different treatment groups as determined by Flow cytometry analysis. ***P < 0.001 vs. IRI, ###P < 0.001 vs. IRI + RMT1-10. B Detection of MPO activity in the different groups. **P < 0.01 vs. IRI, ##P < 0.01 vs. IRI + RMT1-10. C C. ELISA determination of the serum levels of IL-10, TNFα, and IL-6 in the different groups. ***P < 0.001 vs. IRI, ###P < 0.001 vs. IRI + RMT1-10. D qRT-PCR was used to determine the expression levels of Il-10, Tnfa, and Il-6 in the different groups of spleen cells (with red blood cells removed). **P < 0.01 vs. IRI, #P < 0.05, ###P < 0.001 vs. IRI + RMT1-10.
